130 related articles for article (PubMed ID: 19483299)
1. Sensitization of human hepatic stellate cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by leflunomide.
Tang X; Yang J; Li J
Biol Pharm Bull; 2009 Jun; 32(6):963-7. PubMed ID: 19483299
[TBL] [Abstract][Full Text] [Related]
2. Accelerative effect of leflunomide on recovery from hepatic fibrosis involves TRAIL-mediated hepatic stellate cell apoptosis.
Tang X; Yang J; Li J
Life Sci; 2009 Apr; 84(15-16):552-7. PubMed ID: 19385008
[TBL] [Abstract][Full Text] [Related]
3. Wedelolactone exhibits anti-fibrotic effects on human hepatic stellate cell line LX-2.
Xia Y; Chen J; Cao Y; Xu C; Li R; Pan Y; Chen X
Eur J Pharmacol; 2013 Aug; 714(1-3):105-11. PubMed ID: 23791612
[TBL] [Abstract][Full Text] [Related]
4. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis.
Manna SK; Mukhopadhyay A; Aggarwal BB
J Immunol; 2000 Nov; 165(10):5962-9. PubMed ID: 11067959
[TBL] [Abstract][Full Text] [Related]
5. The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage.
Kobayashi Y; Ueyama S; Arai Y; Yoshida Y; Kaneda T; Sato T; Shin K; Kumegawa M; Hakeda Y
J Bone Miner Metab; 2004; 22(4):318-28. PubMed ID: 15221489
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.
Manna SK; Aggarwal BB
J Immunol; 1999 Feb; 162(4):2095-102. PubMed ID: 9973483
[TBL] [Abstract][Full Text] [Related]
7. Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells.
Dietrich S; Krämer OH; Hahn E; Schäfer C; Giese T; Hess M; Tretter T; Rieger M; Hüllein J; Zenz T; Ho AD; Dreger P; Luft T
Clin Cancer Res; 2012 Jan; 18(2):417-31. PubMed ID: 22072733
[TBL] [Abstract][Full Text] [Related]
8. Guggulsterone attenuates activation and survival of hepatic stellate cell by inhibiting nuclear factor kappa B activation and inducing apoptosis.
Kim BH; Yoon JH; Yang JI; Myung SJ; Lee JH; Jung EU; Yu SJ; Kim YJ; Lee HS; Kim CY
J Gastroenterol Hepatol; 2013 Dec; 28(12):1859-68. PubMed ID: 23808824
[TBL] [Abstract][Full Text] [Related]
9. Morin, a dietary flavonoid, exhibits anti-fibrotic effect and induces apoptosis of activated hepatic stellate cells by suppressing canonical NF-κB signaling.
MadanKumar P; NaveenKumar P; Devaraj H; NiranjaliDevaraj S
Biochimie; 2015 Mar; 110():107-118. PubMed ID: 25577997
[TBL] [Abstract][Full Text] [Related]
10. Leflunomide or A77 1726 protect from acetaminophen-induced cell injury through inhibition of JNK-mediated mitochondrial permeability transition in immortalized human hepatocytes.
Latchoumycandane C; Seah QM; Tan RC; Sattabongkot J; Beerheide W; Boelsterli UA
Toxicol Appl Pharmacol; 2006 Nov; 217(1):125-33. PubMed ID: 16979204
[TBL] [Abstract][Full Text] [Related]
11. The active metabolite of leflunomide, A77 1726, protects rat hepatocytes against bile acid-induced apoptosis.
Vrenken TE; Buist-Homan M; Kalsbeek AJ; Faber KN; Moshage H
J Hepatol; 2008 Nov; 49(5):799-809. PubMed ID: 18809221
[TBL] [Abstract][Full Text] [Related]
12. Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells.
Milani D; Zauli G; Rimondi E; Celeghini C; Marmiroli S; Narducci P; Capitani S; Secchiero P
J Neurochem; 2003 Jul; 86(1):126-35. PubMed ID: 12807432
[TBL] [Abstract][Full Text] [Related]
13. [Inhibition of leflunomide active metabolite A771726 on high glucose-induced podocyte apoptosis].
Yuan YC; Yu WM; Li RS; Qiao X
Zhonghua Yi Xue Za Zhi; 2011 Mar; 91(10):703-6. PubMed ID: 21600180
[TBL] [Abstract][Full Text] [Related]
14. Smad2 increases the apoptosis of activated human hepatic stellate cells induced by TRAIL.
Xu F; Zhou D; Meng X; Wang X; Liu C; Huang C; Li J; Zhang L
Int Immunopharmacol; 2016 Mar; 32():76-86. PubMed ID: 26802603
[TBL] [Abstract][Full Text] [Related]
15. Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells.
Oh Y; Park O; Swierczewska M; Hamilton JP; Park JS; Kim TH; Lim SM; Eom H; Jo DG; Lee CE; Kechrid R; Mastorakos P; Zhang C; Hahn SK; Jeon OC; Byun Y; Kim K; Hanes J; Lee KC; Pomper MG; Gao B; Lee S
Hepatology; 2016 Jul; 64(1):209-23. PubMed ID: 26710118
[TBL] [Abstract][Full Text] [Related]
16. Receptor-specific TRAIL as a means to achieve targeted elimination of activated hepatic stellate cells.
Arabpour M; Cool RH; Faber KN; Quax WJ; Haisma HJ
J Drug Target; 2017 Apr; 25(4):360-369. PubMed ID: 27885847
[TBL] [Abstract][Full Text] [Related]
17. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.
Hamilton LC; Vojnovic I; Warner TD
Br J Pharmacol; 1999 Aug; 127(7):1589-96. PubMed ID: 10455314
[TBL] [Abstract][Full Text] [Related]
18. Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL).
Arabpour M; Poelstra K; Helfrich W; Bremer E; Haisma HJ
J Gene Med; 2014; 16(9-10):281-90. PubMed ID: 25088657
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways.
Hu WH; Johnson H; Shu HB
J Biol Chem; 1999 Oct; 274(43):30603-10. PubMed ID: 10521444
[TBL] [Abstract][Full Text] [Related]
20. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
Khanbolooki S; Nawrocki ST; Arumugam T; Andtbacka R; Pino MS; Kurzrock R; Logsdon CD; Abbruzzese JL; McConkey DJ
Mol Cancer Ther; 2006 Sep; 5(9):2251-60. PubMed ID: 16985059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
